Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Dr. Reddy's Laboratories Limited (Unit II)
WARNING LETTER
•Dr. Reddy's Laboratories Limited (Unit II)•March 6, 2015

Dr. Reddy's Laboratories Limited (Unit II) – FDA Warning Letter, Mar 6, 2015

Record Details

The FDA issued a Warning Letter to Dr. Reddy's Laboratories Ltd. following inspections of three facilities in India (CTO Unit VI, CTO Unit V, and Unit-VII) between November 2014 and March 2015. The inspections revealed significant CGMP deviations for Active Pharmaceutical Ingredients (APIs) at CTO Units VI and V, and violations of CGMP regulations for finished pharmaceuticals (21 CFR Parts 210 and 211) at Unit-VII, rendering products adulterated. Key violations at CTO Unit VI included failure to maintain complete laboratory data (e.g., re-testing after failing results, undisclosed "Custom QC laboratory"), uncontrolled electronic data access, non-contemporaneous record-keeping, and inadequate document control. At CTO Unit V, deficiencies involved inadequate investigations into out-of-specification results, improper maintenance of quality-related documents, unauthorized data access for product release in SAP, and failure to identify intermediate storage containers. Unit-VII's violations, some recurrent, included failure to thoroughly investigate discrepancies (e.g., equipment malfunction during sterile filling), inadequate procedures to prevent microbiological contamination (media fill record issues), and insufficient written procedures for production and process controls (e.g., unacceptable visual inspection operator qualification). The FDA questioned the effectiveness of the corporate quality system due to recurrent and long-standing failures. Dr. Reddy's must provide a written response within 15 working days detailing corrective actions, supported by a third-party assessment of data integrity, root causes, and a global CAPA plan. Failure to comply may result in withheld approvals for new applications and refusal of product admission into the U.S.

Company
Dr. Reddy's Laboratories Limited (Unit II)
Inspection date
March 6, 2015
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Maan Abduldayem (Consumer safety Officer )
  • Thomas J. Cosgrove
View Company Profile

ID · f32ac88e-3d0e-492c-96bf-fc45be17856f

Violation Codes7
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 U.S.C. 381(a)(3)FD&C Act 801(a)(3)21 U.S.C. 356C(a)(1)

Full citation text and observation details available on the Dashboard.

Other documents for Dr. Reddy's Laboratories Limited (Unit II)
  • 483 - 2024-11-19November 19, 2024
  • 483 - 2019-07-12July 12, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Dr. Reddy's Laboratories Limited (Unit II)
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.